With novel disease modifying therapeutic products NsGene targets neurological diseases with great medical need. NsGene's proprietary EC BiodeliveryTM technology is capable of delivering therapeutic proteins behind the blood brain barrier. This creates a potential for symptomatic and potentially curative treatments of patients that today have no chance of cure. NsGene products are aimed at the world market.
Market Growth
The overall market for current treatments of central nervous system disorders increased year on year by 8% representing total sales of 77 billion US dollars in 2007. Growth in this market is primarily attributed to CNS disorders such as Alzheimer's disease and Parkinson's disease. Future growth is expected to increase significantly.
NsGene is focusing on neurological indications with more than 100 million patients globally. Today there are no comparable products to NsGene's product candidates on the market. Therefore market penetration is expected to be rapid and significant and the products competitive.
